NLRP3- and AIM2-autonomy in a mouse model of MSU crystal-induced acute inflammation in vivo suggests imiquimod-dependent targeting of Il-1[beta] expression as relevant therapy for gout patients.
Alexandre Mariotte(Inserm), Philippe Georgel(Inserm), Seiamak Bahram(Inserm), Cécile Macquin(Inserm), Jean‐Paul Armspach(Centre National de la Recherche Scientifique), Angélique Pichot(Inserm), Chrystelle Po(Université Paris-Sud), Ismael Aouadi(Inserm), Aurore de Cauwer(Inserm), Emmanuel Chatelus(Laboratoire National de Référence), Jean Sibilia(Immunologie, Immunopathologie et Chimie Thérapeutique), Chérine Abou Fayçal(Université Grenoble Alpes), Nicodème Paul(Inserm), Raphaël Carapito(Inserm), Benoı̂t Frisch(Centre National de la Recherche Scientifique)
Cited by 0
Related Papers
<i>MUC5B</i> Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease
|New England Journal of Medicine|2018|501
Incidence and Prevalence of Systemic Sclerosis: A Systematic Literature Review
|Seminars in Arthritis and Rheumatism|2007|456
Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group
|Annals of the Rheumatic Diseases|2014|432
Hemodynamic Forces Tune the Arrest, Adhesion, and Extravasation of Circulating Tumor Cells
|Developmental Cell|2018|328